What started as a niche trend among bodybuilders and biohackers to lose fat and boost muscle growth is now making its way ...

Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing ...

A federally funded team at the University of Colorado Boulder says its experimental injectable therapy could reverse joint ...

Peptides are gaining popularity online, with creators and other high-profile individuals touting their muscle-building and ...

AmgenAMGN reported first-quarter adjusted earnings of $5.15 per share, which beat the Zacks Consensus Estimate of $4.73 per ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

Q1 2026 Management View "We had a strong first quarter and are well positioned to achieve our objectives for the year," said (Chairman & CEO Robert Bradway), reiterating that 2026 is "a springboard ...

Good afternoon, everyone, and welcome to our first quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay ...

Repatha, a PCSK9 inhibitor, lowers cholesterol well, especially for those intolerant to statins, but its absolute risk ...

Osteoarthritis affects around 600 million people globally. It causes pain, stiffness, and reduced joint function—most commonly in the knees, hands, and hips. There's currently no cure for ...

Knee osteoarthritis is a complex disease that affects the whole joint, including bone, cartilage, ligaments and muscles. Osteoarthritis is a common cause of pain and movement difficulty, affecting 8.3 ...